Drug intelligence / Profile preview

BK1304

Development stage: Unknown
Lead developer: Biken
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

BK1304 is an intranasal influenza vaccine candidate developed by the Research Foundation for Microbial Diseases of Osaka University (BIKEN). It is designed to provide protection against influenza through mucosal administration, which can induce both local mucosal IgA and systemic IgG immune responses. The pediatric formulation is currently in Phase 2 clinical development in Japan (jRCT2031200156), while the adult formulation has progressed to Phase 3 (jRCT2080224074).

Other names: BK1304 (pediatric)intranasal influenza vaccine (pediatric)

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on BK1304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK1304.

Explore the full profile